Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $313,454.45 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Colleen Tupper also recently made the following trade(s):

• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $29.46 on Friday. The stock has a market cap of $927.58 million, a PE ratio of 12.70 and a beta of 0.99. The business has a fifty day simple moving average of $30.85 and a 200-day simple moving average of $32.96. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12 month low of $27.28 and a 12 month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the company. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $40,000. TD Private Client Wealth LLC boosted its position in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in Collegium Pharmaceutical during the third quarter valued at $72,000. KBC Group NV boosted its position in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the subject of several research reports. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.